{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:11:18Z","timestamp":1782889878606,"version":"3.54.5"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ucl.2008.07.006","type":"journal-article","created":{"date-parts":[[2008,11,7]],"date-time":"2008-11-07T20:09:02Z","timestamp":1226088542000},"page":"573-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Molecular Biology of Renal Cortical Tumors"],"prefix":"10.1016","volume":"35","author":[{"given":"Tobias","family":"Klatte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan J.","family":"Pantuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ucl.2008.07.006_bib1","first-page":"71","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO classification of the renal tumors of the adults","volume":"49","author":"Lopez-Beltran","year":"2006","journal-title":"Eur Urol"},{"issue":"5 Suppl","key":"10.1016\/j.ucl.2008.07.006_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2005.06.112","article-title":"Role of molecular markers in the diagnosis and therapy of renal cell carcinoma","volume":"66","author":"Lam","year":"2005","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.ucl.2008.07.006_bib4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM197909133011107","article-title":"Hereditary renal-cell carcinoma associated with a chromosomal translocation","volume":"301","author":"Cohen","year":"1979","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ucl.2008.07.006_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.2910430313","article-title":"Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas","volume":"43","author":"Kovacs","year":"1989","journal-title":"Int J Cancer"},{"issue":"4563","key":"10.1016\/j.ucl.2008.07.006_bib6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1126\/science.7112106","article-title":"Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells","volume":"217","author":"Pathak","year":"1982","journal-title":"Science"},{"issue":"5112","key":"10.1016\/j.ucl.2008.07.006_bib7","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"issue":"2 Pt 2","key":"10.1016\/j.ucl.2008.07.006_bib8","doi-asserted-by":"crossref","first-page":"671s","DOI":"10.1158\/1078-0432.CCR-06-1870","article-title":"Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics","volume":"13","author":"Linehan","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.006_bib9","article-title":"Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival in patients with renal cell carcinoma (RCC)","volume":"77","author":"Patard","year":"2007","journal-title":"J\u00a0Urol (Suppl)"},{"issue":"3","key":"10.1016\/j.ucl.2008.07.006_bib10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/01.ju.0000081122.57148.ec","article-title":"Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality","volume":"170","author":"M\u00e9jean","year":"2003","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2008.07.006_bib11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.onc.1201983","article-title":"Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours","volume":"17","author":"Fischer","year":"1998","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.006_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/1727","article-title":"Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas","volume":"20","author":"Zhuang","year":"1998","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.ucl.2008.07.006_bib13","first-page":"1719","article-title":"Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene","volume":"58","author":"Schmidt","year":"1998","journal-title":"Cancer Res"},{"issue":"4 Pt 1","key":"10.1016\/j.ucl.2008.07.006_bib14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/01.ju.0000139583.63354.e0","article-title":"Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the MET proto-oncogene","volume":"172","author":"Schmidt","year":"2004","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2008.07.006_bib15","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","article-title":"Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer","volume":"177","author":"Grubb","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.006_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ucl.2008.07.006_bib17","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1001\/archderm.1977.01640120042005","article-title":"Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons","volume":"113","author":"Birt","year":"1977","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib18","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1097\/01.ju.0000154629.45832.30","article-title":"Evaluation and management of renal tumors in the\u00a0Birt-Hogg-Dube syndrome","volume":"173","author":"Pavlovich","year":"2005","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.ucl.2008.07.006_bib19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jnci\/dji154","article-title":"High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors","volume":"97","author":"Vocke","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.006_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0959-437X(00)00152-0","article-title":"The von Hippel-Lindau tumor suppressor protein","volume":"11","author":"Ivan","year":"2001","journal-title":"Curr Opin Genet Dev"},{"issue":"5556","key":"10.1016\/j.ucl.2008.07.006_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1068592","article-title":"Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch","volume":"295","author":"Lando","year":"2002","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ucl.2008.07.006_bib22","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.ucl.2008.07.006_bib23","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","article-title":"Purification and characterization of hypoxia-inducible factor 1","volume":"270","author":"Wang","year":"1995","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.006_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.bjc.6600996","article-title":"Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome","volume":"89","author":"Atzpodien","year":"2003","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ucl.2008.07.006_bib25","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1073\/pnas.94.9.4273","article-title":"A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development","volume":"94","author":"Ema","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.ucl.2008.07.006_bib26","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1074\/jbc.272.13.8581","article-title":"Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway","volume":"272","author":"Hogenesch","year":"1997","journal-title":"J Biol Chem"},{"issue":"30","key":"10.1016\/j.ucl.2008.07.006_bib27","doi-asserted-by":"crossref","first-page":"17771","DOI":"10.1074\/jbc.271.30.17771","article-title":"DNA binding, and transactivation properties of hypoxia-inducible factor 1","volume":"271","author":"Jiang","year":"1996","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.006_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.11.1.72","article-title":"Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells","volume":"11","author":"Tian","year":"1997","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.006_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/91.2.143","article-title":"aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia","volume":"91","author":"Thrash-Bingham","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"36","key":"10.1016\/j.ucl.2008.07.006_bib31","doi-asserted-by":"crossref","first-page":"32405","DOI":"10.1074\/jbc.C200328200","article-title":"Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus","volume":"277","author":"Makino","year":"2002","journal-title":"J Biol Chem"},{"issue":"4 Pt 1","key":"10.1016\/j.ucl.2008.07.006_bib32","doi-asserted-by":"crossref","first-page":"C1172","DOI":"10.1152\/ajpcell.1996.271.4.C1172","article-title":"Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension","volume":"271","author":"Jiang","year":"1996","journal-title":"Am J Physiol"},{"issue":"14","key":"10.1016\/j.ucl.2008.07.006_bib33","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1073\/pnas.95.14.7987","article-title":"Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway","volume":"95","author":"Huang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6733","key":"10.1016\/j.ucl.2008.07.006_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"issue":"36","key":"10.1016\/j.ucl.2008.07.006_bib35","doi-asserted-by":"crossref","first-page":"22642","DOI":"10.1074\/jbc.272.36.22642","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes","volume":"272","author":"Salceda","year":"1997","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.ucl.2008.07.006_bib36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat Cell Biol"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Pt 2","key":"10.1016\/j.ucl.2008.07.006_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1242\/jcs.01617","article-title":"Role of CBP in regulating HIF-1-mediated activation of transcription","volume":"118","author":"Ruas","year":"2005","journal-title":"J\u00a0Cell Sci"},{"issue":"20","key":"10.1016\/j.ucl.2008.07.006_bib39","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev"},{"issue":"6 Pt 1","key":"10.1016\/j.ucl.2008.07.006_bib40","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","article-title":"The genetic basis of cancer of the kidney","volume":"170","author":"Linehan","year":"2003","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.ucl.2008.07.006_bib41","first-page":"4641","article-title":"Pathobiology, prognosis, and targeted therapy for\u00a0renal cell carcinoma: exploiting the hypoxia-induced pathway","volume":"9","author":"Pantuck","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ucl.2008.07.006_bib42","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-05-2670","article-title":"Regulation of E-cadherin expression by VHL and hypoxia-inducible factor","volume":"66","author":"Esteban","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib43","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/0008-5472.CAN-05-3719","article-title":"Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B","volume":"66","author":"Krishnamachary","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.006_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","article-title":"Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene","volume":"3","author":"Pennacchietti","year":"2003","journal-title":"Cancer Cell"},{"issue":"6955","key":"10.1016\/j.ucl.2008.07.006_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01874","article-title":"Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL","volume":"425","author":"Staller","year":"2003","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ucl.2008.07.006_bib46","first-page":"3915","article-title":"Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2","volume":"59","author":"Feldser","year":"1999","journal-title":"Cancer Res"},{"issue":"41","key":"10.1016\/j.ucl.2008.07.006_bib47","doi-asserted-by":"crossref","first-page":"38205","DOI":"10.1074\/jbc.M203781200","article-title":"Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells","volume":"277","author":"Fukuda","year":"2002","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.ucl.2008.07.006_bib48","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","article-title":"HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression","volume":"21","author":"Laughner","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.ucl.2008.07.006_bib49","first-page":"1541","article-title":"Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics","volume":"60","author":"Zhong","year":"2000","journal-title":"Cancer Res"},{"issue":"40","key":"10.1016\/j.ucl.2008.07.006_bib50","doi-asserted-by":"crossref","first-page":"41521","DOI":"10.1074\/jbc.M405164200","article-title":"Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling","volume":"279","author":"Hirota","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.006_bib51","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1074\/jbc.M308197200","article-title":"Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling","volume":"279","author":"Kasuno","year":"2004","journal-title":"J Biol Chem"},{"issue":"50","key":"10.1016\/j.ucl.2008.07.006_bib52","doi-asserted-by":"crossref","first-page":"48403","DOI":"10.1074\/jbc.M209114200","article-title":"Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms","volume":"277","author":"Pag\u00e9","year":"2002","journal-title":"J Biol Chem"},{"issue":"35","key":"10.1016\/j.ucl.2008.07.006_bib53","doi-asserted-by":"crossref","first-page":"26765","DOI":"10.1016\/S0021-9258(19)61441-9","article-title":"Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells","volume":"275","author":"Richard","year":"2000","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.ucl.2008.07.006_bib54","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr Opin Cell Biol"},{"issue":"5573","key":"10.1016\/j.ucl.2008.07.006_bib55","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.006_bib56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.006_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","article-title":"The protein kinase B\/Akt signalling pathway in human malignancy","volume":"14","author":"Nicholson","year":"2002","journal-title":"Cell Signal"},{"issue":"22","key":"10.1016\/j.ucl.2008.07.006_bib59","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","article-title":"Cellular survival: a play in three Akts","volume":"13","author":"Datta","year":"1999","journal-title":"Genes Dev"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.006_bib60","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.semcdb.2004.01.002","article-title":"PI 3-kinase, Akt and cell survival","volume":"15","author":"Downward","year":"2004","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.ucl.2008.07.006_bib61","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.006_bib62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4161\/cc.2.4.433","article-title":"Multiple roles of the PI3K\/PKB (Akt) pathway in cell cycle progression","volume":"2","author":"Liang","year":"2003","journal-title":"Cell Cycle"},{"issue":"Pt 3","key":"10.1016\/j.ucl.2008.07.006_bib63","first-page":"573","article-title":"United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase\/Akt pathway to mammalian target of rapamycin (mTOR) signalling","volume":"31","author":"Manning","year":"2003","journal-title":"Biochem Soc Trans"},{"issue":"16","key":"10.1016\/j.ucl.2008.07.006_bib64","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.006_bib65","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1073\/pnas.93.4.1689","article-title":"The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase","volume":"93","author":"Damen","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.ucl.2008.07.006_bib66","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","article-title":"New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway","volume":"96","author":"Cantley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.ucl.2008.07.006_bib67","first-page":"8330","article-title":"Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein Bad","volume":"63","author":"Eisenmann","year":"2003","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.006_bib68","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-04-0297","article-title":"Raf kinase as a target for anticancer therapeutics","volume":"4","author":"Sridhar","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ucl.2008.07.006_bib69","first-page":"219","article-title":"Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs","volume":"5","author":"Kohno","year":"2003","journal-title":"Prog Cell Cycle Res"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.006_bib70","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0092-8674(00)80753-9","article-title":"How the cyclin became a cyclin: regulated proteolysis in the cell cycle","volume":"97","author":"Koepp","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.ucl.2008.07.006_bib71","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.17.1.739","article-title":"Degradation of cell proteins and the generation of MHC class I-presented peptides","volume":"17","author":"Rock","year":"1999","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.006_bib72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/emboj\/19.1.94","article-title":"Recognition of the polyubiquitin proteolytic signal","volume":"19","author":"Thrower","year":"2000","journal-title":"EMBO J"},{"issue":"6152","key":"10.1016\/j.ucl.2008.07.006_bib73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/331192a0","article-title":"Identity of the 19S \u2018prosome\u2019 particle with the large multifunctional protease complex of mammalian cells (the proteasome)","volume":"331","author":"Arrigo","year":"1988","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib74","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/S0021-9258(17)35950-1","article-title":"Ubiquitin-lysozyme conjugates. Identification and characterization of an ATP-dependent protease from rabbit reticulocyte lysates","volume":"261","author":"Hough","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ucl.2008.07.006_bib75","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib76","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0092-8674(00)81603-7","article-title":"A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3","volume":"94","author":"Glickman","year":"1998","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.006_bib77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ucl.2008.07.006_bib78","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.006_bib79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"9605","key":"10.1016\/j.ucl.2008.07.006_bib80","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.006_bib81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ucl.2008.07.006_bib82","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.ucl.2008.07.006_bib83","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.006_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-5347(05)00040-6","article-title":"A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma","volume":"175","author":"Bleumer","year":"2006","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.ucl.2008.07.006_bib85","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1200\/JCO.2005.05.0344","article-title":"Medullary renal cell carcinoma and response to therapy with bortezomib","volume":"24","author":"Ronnen","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014308000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014308000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:21:58Z","timestamp":1758806518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014308000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0094014308000682"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2008.07.006","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Biology of Renal Cortical Tumors","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2008.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}